MIGDEN, M. R.; BERKIN, C.; CHANG, A. L.; AL., E. Interim Analysis of Phase 2 Results for Cemiplimab, a Human Monoclonal Antibody to Programmed Death-1, in Patients with Locally Advanced Cutaneous Squamous Cell Carcinoma. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 2, p. S77, 2018. DOI: 10.25251/skin.2.supp.77. Disponível em: https://jofskin.org/33014/index.php/skin/article/view/473. Acesso em: 4 jul. 2024.